REPL Earnings Date: Feb 2, 2027 (Estimated) — Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is REPL's next earnings date?
Replimune Group, Inc. (REPL) is expected to report Q3 2027 earnings on Tuesday, February 2, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.78 on revenue of $6.8M.
How did REPL do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q2 2027), Replimune Group, Inc. posted EPS of -$0.54 versus the -$0.78 estimate, a beat of 31.1%. The stock's 1-day post-earnings move was +23.1%.
How much does REPL stock move after earnings?
REPL beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About Replimune Group, Inc.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
🤖 AI Earnings Analysis
Replimune’s Q2 loss narrowed to $0.54 per share from $0.90 year over year, beating estimates by $0.24, but no revenue or catalyst was reported; for this clinical-stage biotech, the loss beat alone is not evidence of durable progress.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q2 2027 | -0.78 | -0.54 | +31.12% | — | ✅ Beat | +23.07% | — | — |
| 2026-08-14 | Q1 2027 | -0.69 | -0.72 | +5.26% | $0 | ❌ Miss | -1.45% | -7.50% | -13.69% |
| 2026-06-29 | Q4 2026 | -0.70 | -0.76 | -8.57% | $0 | ❌ Miss | -3.70% | -1.38% | -54.00% |
| 2026-02-03 | Q3 2026 | -0.83 | -0.77 | +7.23% | $0 | ✅ Beat | +5.81% | +11.47% | +3.94% |
| 2025-11-06 | Q2 2026 | -0.82 | -0.90 | -9.76% | $0 | ❌ Miss | -0.93% | +5.36% | +23.66% |
| 2025-02-12 | Q3 2025 | -0.75 | -0.79 | -5.33% | $0 | ❌ Miss | +7.32% | +7.24% | -7.70% |
| 2024-11-12 | Q2 2025 | -0.78 | -0.68 | +12.82% | $0 | ✅ Beat | -2.48% | -13.84% | +1.12% |
| 2024-08-08 | Q1 2025 | -0.85 | -0.78 | +8.24% | $0 | ✅ Beat | +2.72% | +7.17% | +12.72% |
Showing last 8 quarters.